Rare genetic disease
Lysosomal storage disorders and orphan indications with substantial unmet needs.
Partnership Portal
Your expertise.
Our shared possibility.
Connect your programme with Dawn’s delivery science. Explore a collaboration shaped around the question you need to solve.
Explore partnership portal01 / Complementary by design
Bring a question.
Build a shared path.
Expertise, connected.
Two delivery platforms.
A flexible collaboration model.
Our mission depends on high-quality collaboration. Dawn offers partners a focused preclinical platform company with differentiated tissue-targeting capabilities, milestone-based development planning, and flexible partnership structures across licensing, co-development, translational execution, and future programme expansion.
- sLV
- Stealth lentiviral delivery
- iLNP
- Targeted lipid nanoparticles
- Focus
- Hard-to-target tissues
- Stage
- Preclinical development
02 / Find your collaboration
Six ways to contribute.
One shared ambition.
Choose a route to explore how your expertise could connect with Dawn.
Co-development
Build a programme together
Partner with Dawn to co-develop selected programmes, particularly new applications of our delivery platforms, with shared development costs, milestones, and commercial rights designed around the needs of each indication.
Discuss this partnership03 / Where we connect
Focused needs.
Complementary expertise.
Delivery innovation
Targeting chemistry, LNP optimisation and genetic payload development.
Tissue targeting
CNS, joint and cartilage applications supported by preclinical research.
04 / From introduction to collaboration
A clear path to working together.
- 01
Introduce your idea
Share your area of interest and the question you want to explore.
- 02
Assess the fit
Our team reviews the scientific and strategic alignment.
- 03
Explore the detail
Agree confidentiality arrangements before sharing sensitive material.
- 04
Shape the partnership
Define scope, responsibilities, development milestones and terms.
05 / Responsible collaboration
Confidence starts with clarity.
A staged approach to disclosure.
Begin with a non-confidential overview. Technical details, unpublished intellectual property and commercially sensitive materials can be discussed through a controlled diligence process with appropriate agreements.
Explore our IP approach
Protect the science. Enable the conversation.
Start a conversation
Progress begins
with connection.
Tell us what you have in mind. Prepare an email to the right team at Dawn.
info@dawntherapeutics.comClear answers
Questions, answered.
How can an organisation partner with Dawn?
Potential collaborators can start with a non-confidential enquiry about licensing, co-development, research, manufacturing, safety or patient partnerships. Appropriate confidentiality arrangements precede sensitive technical discussions.
Discover more